|
Total
|
243a
|
153
|
28
|
33
|
13
|
12
|
|
Age (years) (mean)
|
58.9 ± 20.1
|
59.5 ± 19.7
|
53.1 ± 17.2
|
59.4 ± 19.5
|
59.2 ± 23.3
|
58,0 ± 30,7
|
|
Age range (years)
|
0-97
|
0-97
|
18-84
|
0-90
|
2-91
|
0-89
|
|
Percentage of male patients
|
66.7
|
60.1
|
82.1
|
81.8
|
61.5
|
83.3
|
|
Hospitalization abroad during previous 6 months
|
32 patientsb
|
N = 10
|
N = 11
|
N = 7
|
N = 2
|
N = 1
|
|
Iran
|
Egypt
|
Egypt
|
Qatar
|
Sri Lanka
|
|
Kuwait
|
Brasil
|
Greece
|
India
| |
|
Brasil
|
Ukraine
|
Nicaragua
| | |
|
Qatar
|
Qatar
|
Italy
| | |
|
India
|
Kosovo
|
India (n = 2)
| | |
|
Egypt
|
Russia
|
Turkey
| | |
|
Nicaragua
|
India
| | | |
|
Venezuela
|
Thailand
| | | |
|
Russia
|
(n = 2)
| | | |
|
Macedonia
|
Turkey
| | | |
| |
Morocco
| | | |
|
Place of residence abroad
|
N = 21 (8.6%)
|
N = 11
|
N = 6
|
N = 2
|
N = 2
| |
|
Egypt
|
Algeria
|
Egypt
|
India
| |
|
Iran
|
Egypt
|
India
|
Egypt
| |
|
India
|
Qatar
| | | |
|
Kuwait
|
Kuwait
| | | |
|
Macedonia
|
Russia (n = 2)
| | | |
|
Qatar (n = 2)
| | | | |
|
Russia
| | | | |
|
Saudi Arabia
| | | | |
|
Ukraine
| | | | |
|
Venezuela
| | | | |
|
Infection (%)
|
29.7
|
24.2
|
28.6
|
30.3
|
23.1
|
50.0
|
|
Carbapenemase (cases)
|
32 casesc
|
Metallo-ß-lactamase, unspecified (n = 3)
|
OXA-23-like (n = 7)
|
OXA-23-like (n = 1)
|
OXA-48 (n = 4)
| |
|
VIM-1 (n = 1)
|
NDM-1 (n = 1)
|
OXA-48 (n = 4)
|
NDM-7 (n = 1)
| |
|
VIM-2 (n = 3)
| |
NDM, not further specified (n = 3)
| | |
| | |
KPC-2 (n = 1)
| | |
| | |
KPC-3 (n = 1)
| | |
